StockMarketWire.com - Point-of-care company EKF Diagnostics upgraded its outlook on full-year performance after receiving an initial order worth £3m from a partner from the private sector to supply its sample collection device, to be used in a Covid-19 testing programme for UK staff.
The new supply contract came on the back of the $14.1m orders reported for the three-month period ending 30 September 2020.
Due to the continued demand for PrimeStore MTM, full-year performance was likely to 'further exceed, and possibly significantly exceed, previously revised management expectations,' the company said.
At 9:43am: [LON:EKF] EKF Diagnostics Holdings PLC share price was +5.75p at 55.25p
Story provided by StockMarketWire.com
Shares Magazine
Shares is the leading weekly publication for retail investors. It is packed with investment ideas, news and educational material to help build and run portfolios and get more from your money.
Investor Events
Shares puts on free Investor Events throughout the year across the country. They provide an opportunity for investors to learn more about companies on the stock market and hear from a range of investment experts including fund managers and Shares journalists.